30 Day Trial

NuVasive 3Q17 Revenue +3.2% vs. 3Q16

Share:

NuVasive reported 3Q17 revenue of US $247.4MM, +3.2% vs. 3Q16, and year-to-date revenue of $757.9MM, +9.7% vs. the prior year. 

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.